Shares of Omnicell, Inc. (NASDAQ:OMCL) have been given an average rating of “Buy” by the twelve brokerages that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $47.00.

OMCL has been the subject of a number of recent analyst reports. TheStreet downgraded Omnicell from a “b-” rating to a “c+” rating in a report on Thursday, May 4th. ValuEngine upgraded Omnicell from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded Omnicell from a “sell” rating to a “hold” rating in a report on Friday, May 26th. Piper Jaffray Companies cut Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 target price for the company. in a research note on Friday, April 21st. Finally, CIBC boosted their target price on Omnicell from $43.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday, April 26th.

In other Omnicell news, Chairman Randall A. Lipps sold 9,900 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $43.00, for a total value of $425,700.00. Following the completion of the transaction, the chairman now directly owns 208,982 shares of the company’s stock, valued at $8,986,226. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director James T. Judson sold 12,148 shares of the business’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $41.50, for a total value of $504,142.00. Following the completion of the transaction, the director now directly owns 19,130 shares of the company’s stock, valued at $793,895. The disclosure for this sale can be found here. Over the last three months, insiders sold 69,473 shares of company stock valued at $2,869,438. Insiders own 3.75% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of OMCL. Russell Investments Group Ltd. purchased a new position in Omnicell during the fourth quarter valued at $1,628,000. Comerica Bank boosted its position in Omnicell by 2.4% in the fourth quarter. Comerica Bank now owns 68,676 shares of the company’s stock valued at $2,290,000 after buying an additional 1,634 shares in the last quarter. State Street Corp boosted its position in Omnicell by 8.1% in the fourth quarter. State Street Corp now owns 802,579 shares of the company’s stock valued at $27,210,000 after buying an additional 60,375 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Omnicell by 2.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,798,592 shares of the company’s stock valued at $60,972,000 after buying an additional 47,138 shares in the last quarter. Finally, Martingale Asset Management L P boosted its position in Omnicell by 83.5% in the fourth quarter. Martingale Asset Management L P now owns 125,912 shares of the company’s stock valued at $4,269,000 after buying an additional 57,300 shares in the last quarter. 96.35% of the stock is owned by institutional investors.

WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/06/19/omnicell-inc-omcl-given-average-recommendation-of-buy-by-brokerages.html.

Shares of Omnicell (NASDAQ OMCL) traded down 1.15% during midday trading on Monday, reaching $42.85. The company’s stock had a trading volume of 86,043 shares. The company’s market cap is $1.59 billion. Omnicell has a 12 month low of $30.35 and a 12 month high of $43.50. The stock has a 50-day moving average of $41.55 and a 200 day moving average of $38.06.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, May 4th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.36. The business had revenue of $150.90 million during the quarter, compared to the consensus estimate of $152.63 million. Omnicell had a positive return on equity of 2.66% and a negative net margin of 1.45%. The firm’s revenue was down 12.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.35 earnings per share. On average, analysts predict that Omnicell will post $1.28 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.